Strongbridge Biopharma plc (SBBP) Expected to Post Earnings of -$0.59 Per Share

Equities analysts expect Strongbridge Biopharma plc (NASDAQ:SBBP) to report earnings per share (EPS) of ($0.59) for the current quarter, according to Zacks. Four analysts have provided estimates for Strongbridge Biopharma’s earnings, with estimates ranging from ($0.71) to ($0.46). Strongbridge Biopharma posted earnings of ($0.31) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 90.3%. The business is expected to report its next earnings report on Monday, March 11th.

According to Zacks, analysts expect that Strongbridge Biopharma will report full-year earnings of ($1.74) per share for the current financial year, with EPS estimates ranging from ($1.89) to ($1.59). For the next fiscal year, analysts expect that the business will report earnings of ($0.99) per share, with EPS estimates ranging from ($1.15) to ($0.82). Zacks’ EPS calculations are an average based on a survey of research firms that follow Strongbridge Biopharma.

Strongbridge Biopharma (NASDAQ:SBBP) last released its earnings results on Wednesday, October 31st. The biotechnology company reported ($0.44) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by ($0.06). The firm had revenue of $5.35 million for the quarter, compared to the consensus estimate of $5.48 million.

Several analysts recently commented on the stock. ValuEngine cut shares of Strongbridge Biopharma from a “buy” rating to a “hold” rating in a research note on Monday, November 12th. Laidlaw assumed coverage on shares of Strongbridge Biopharma in a research note on Tuesday, December 18th. They issued a “buy” rating and a $11.00 price objective for the company. Cantor Fitzgerald set a $17.00 price objective on shares of Strongbridge Biopharma and gave the company a “buy” rating in a research note on Tuesday, October 2nd. Finally, Zacks Investment Research cut shares of Strongbridge Biopharma from a “hold” rating to a “sell” rating in a research note on Wednesday, November 7th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. Strongbridge Biopharma has an average rating of “Hold” and an average price target of $14.13.

In other news, major shareholder Associates L.L.C. Cdk purchased 49,397 shares of the stock in a transaction dated Thursday, December 27th. The stock was acquired at an average cost of $3.99 per share, for a total transaction of $197,094.03. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 4.20% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. Laurion Capital Management LP purchased a new stake in Strongbridge Biopharma in the second quarter valued at approximately $101,000. Dynamic Technology Lab Private Ltd purchased a new stake in Strongbridge Biopharma during the second quarter worth approximately $110,000. Cubist Systematic Strategies LLC purchased a new stake in Strongbridge Biopharma during the second quarter worth approximately $130,000. Jane Street Group LLC purchased a new stake in Strongbridge Biopharma during the second quarter worth approximately $154,000. Finally, Citadel Advisors LLC purchased a new stake in Strongbridge Biopharma during the third quarter worth approximately $157,000. Institutional investors and hedge funds own 65.68% of the company’s stock.

Shares of NASDAQ SBBP opened at $4.54 on Wednesday. The company has a quick ratio of 3.11, a current ratio of 3.38 and a debt-to-equity ratio of 8.76. Strongbridge Biopharma has a 52 week low of $3.82 and a 52 week high of $9.25. The stock has a market capitalization of $212.06 million, a P/E ratio of -3.13 and a beta of 0.09.

About Strongbridge Biopharma

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada.

Read More: Why investors pay attention to retained earnings

Get a free copy of the Zacks research report on Strongbridge Biopharma (SBBP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply